CollPlant Seeks Nasdaq Upgrade
Ticker: CLGN · Form: 6-K · Filed: Sep 12, 2025 · CIK: 1631487
Sentiment: neutral
Topics: listing-transfer, sec-filing, nasdaq
TL;DR
CollPlant is moving its Nasdaq listing to a higher tier, aiming for more visibility.
AI Summary
CollPlant Biotechnologies Ltd. submitted a voluntary application on September 12, 2025, to transfer the listing of its ordinary shares from the Nasdaq Capital Market to the Nasdaq Global Select Market. This move is intended to enhance the company's visibility and potentially improve trading liquidity.
Why It Matters
Moving to a higher-tier Nasdaq market could signal increased investor confidence and potentially lead to better access to capital for CollPlant's regenerative medicine technologies.
Risk Assessment
Risk Level: low — The filing is a routine administrative update regarding a stock exchange listing transfer, with no immediate financial or operational risks disclosed.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- Nasdaq Capital Market (company) — Current exchange
- Nasdaq Global Select Market (company) — Target exchange
FAQ
What is the primary purpose of this filing?
The primary purpose of this filing is to report CollPlant Biotechnologies Ltd.'s voluntary application to transfer the listing of its ordinary shares from the Nasdaq Capital Market to the Nasdaq Global Select Market.
When was this application submitted?
The application was submitted as part of a report filed on September 12, 2025.
Which stock exchange is CollPlant currently listed on?
CollPlant is currently listed on the Nasdaq Capital Market.
What is the intended new exchange for CollPlant's shares?
The intended new exchange is the Nasdaq Global Select Market.
What is the expected benefit of this transfer?
The company expects the transfer to enhance its visibility and potentially improve trading liquidity.
Filing Stats: 262 words · 1 min read · ~1 pages · Grade level 15.3 · Accepted 2025-09-12 16:15:02
Filing Documents
- ea0256949-6k_collplant.htm (6-K) — 9KB
- 0001213900-25-087226.txt ( ) — 10KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: September 12, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2